Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the years, but the range of approved drugs has expanded. Semaglutide and tirzepatide are the most commonly used today. Primary care providers play an important role in the individualized medical management of overweight patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – angiosarcoma
- Pediatric epilepsy
Diazepam nasal spray for infants
- Findings from research on the generalization of exposure therapy
Treatment of comorbid anxiety
- Symptom-free despite asthma?
Asthma treatment requirements have increased
- Phytotherapy for rhinosinusitis
Evidence, active substances and clinical classification for medical practice
- Contact eczema
Causes and prevention at work
- Pulmonary hypertension
PH and lung diseases
- Respiratory infections: viral bronchitis or bacterial pneumonia?